H.C. Wainwright restates Ovid Therapeutics stock rating at buy
Corroborated by 2 sources from 2 publishers
TL;DR
Generate Biomedicines, Inc H.C. Wainwright reiterates Cardiff Oncology stock rating at buy.
Sources
1
Yahoo Finance News
https://finance.yahoo.com/sectors/healthcare/articles/h-c-wainwright-initiates-coverage-001146243.html
2
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-cardiff-oncology-stock-rating-at-buy-93CH-4623028
3
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-meiragtx-stock-rating-on-gene-therapy-progress-93CH-4623029
4
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-ovid-therapeutics-stock-rating-at-buy-93CH-4623032
5
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-legend-biotech-stock-rating-on-pipeline-progress-93CH-4623033
6
Investing.com News
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-emergent-biosolutions-stock-rating-on-refinancing-93CH-4623035